67 related articles for article (PubMed ID: 11865645)
1. Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
Suzuki Y; Tokinaga-Uchiyama A; Mizushima T; Maruyama Y; Mogami T; Shikata N; Ikeda A; Yamamoto H; Miyagi E
BMC Cancer; 2018 Oct; 18(1):973. PubMed ID: 30314462
[TBL] [Abstract][Full Text] [Related]
2. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
3. Multiple serum markers in patients with endometrial cancer.
Panici PB; Scambia G; Baiocchi G; Perrone L; Greggi S; Battaglia F; Mancuso S
Gynecol Obstet Invest; 1989; 27(4):208-12. PubMed ID: 2744625
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumour markers in endometrial cancer.
Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY
Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009
[TBL] [Abstract][Full Text] [Related]
5. Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA 125, squamous cell carcinoma antigen, CA 19.9 and CA 15.3.
Matorras R; Rodríguez-Escuderoi FJ; Diez J; Genollá J; Cruz Fombellida J; Ruibal A
Acta Obstet Gynecol Scand; 1992 Aug; 71(6):458-64. PubMed ID: 1326844
[TBL] [Abstract][Full Text] [Related]
6. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
Geyer H; Schwörer D; Pfleiderer A
Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic significance of tumor markers for gynecologic malignancies].
Aoki D; Hirasawa A; Susumu N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
[TBL] [Abstract][Full Text] [Related]
8. [Experiences with the squamous cell carcinoma antigen, a new tumor marker for cancer of the uterine cervix].
Meier W; Eiermann W; Stieber P; Fateh-Moghadam A; Hepp H
Geburtshilfe Frauenheilkd; 1989 Jul; 49(7):625-9. PubMed ID: 2777050
[TBL] [Abstract][Full Text] [Related]
9. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
10. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
11. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
13. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
